Kala Pharmaceuticals scores $22.5 mln
Kala Pharmaceuticals said Wednesday that it has closed $22.5 million in Series B financing. Ysios Capital led the round with participation from Crown Venture Fund, Lux Capital, Polaris Partners and Third Rock Ventures. In addition to the funding, Dr. Karen Wagner, a general partner at Ysios Capital, has been added to Kala’s board of directors. Based in Waltham, Mass., Kala Pharmaceuticals is a developer of treatments for ocular diseases.
23 April 2014•3 mins read
